Author:
Navarro Navarro I.,Jiménez Gallo D.,Fernández Morano M.T.,Villegas Romero I.,Catalina Fernández M.I.,Linares Barrios M.
Reference10 articles.
1. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF V600 mutation-positive melanoma (NeoCombi): A single-arm, open-label, single-centre, phase 2 trial;Long;Lancet Oncol,2019
2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1);Eisenhauer;Eur J Cancer,2009
3. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma;Tetzlaff;Ann Oncol Off J Eur Soc Med Oncol,2018
4. Adjuvant dabrafenib plus trametinib in stage III BRAF -mutated melanoma;Long;N Engl J Med,2017
5. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma;Weber;N Engl J Med,2017